N-PORT filing recap · July 2020

What did ARK Genomic Revolution ETF buy in July 2020?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.59B

Positions

Estimated turnover

48.5%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

VRTXVertex Pharmaceuticals Inc / Ma$29.65Mreported value+109.0K shares SDGRSchrodinger, Inc.$13.17Mreported value+181.9K shares ACCDAccolade Inc$8.34Mreported value+257.2K shares PHRPhreesia, Inc.$8.18Mreported value+272.2K shares BLIUSDPhenomex Inc$1.85Mreported value+30.9K shares

Increased positions

CRSPCrispr Therapeutics AG$175.27Mreported value+788.4K shares+62.4%NVTAInvitae Corp$170.47Mreported value+1.62M shares+38.3%ILMNIllumina, Inc.$91.24Mreported value+19.1K shares+8.7%CGENCompugen Ltd$81.84Mreported value+1.44M shares

Reduced positions

ARCTArcturus Therapeutics Holdings Inc.$102.66Mreported value-63.1K shares-3.1%NTLAIntellia Therapeutics, Inc.$44.16Mreported value-91.9K shares-3.6%INOInovio Pharmaceuticals, Inc.$17.55Mreported value-157.3K shares-14.8%ONVOOrganovo Holdings Inc$5.02Mreported value-25.8K shares

Exited positions

BLCMEURBellicum Pharmaceuticals Inc$280prior reported value-56 shares-100.0%